A few thoughts:
First - for everyone expecting RGBP to skyrocket on every PR, get off this board and look at what is taking place in the overall market today.
When people act negatively to what should be seen as good news or encouraging news, one must ask, "What's up with that?"
Adding the Dr. who was the lead writer on the HemaXellerate peer reviewed paper to the Scientific Advisory Team can only be seen as a positive in conjunction with the safety trials and protocol needed for FDA approval of HemaXellerate. If Koos had hired someone without any experience (to save money or for whatever reason), that would be a terrible sign, but let's be positive that we now have the person who wrote the paper on HemaXellerate on the team preparing for its FDA approval of clinical trials, because trial approval is not the ultimate goal, it's the success of the trials themselves. Today's development is a positive and can only give hope that HemaXellerate is not dead in the water.
If you expect RGBP to be worthless, why waste your time on this board? This board should be used for exchange of facts and developments and the speculation associated, not for those not interested in the company's success' constant banter.
I did not expect today's PR, but I also see it along with previous comments of others as a good sign and necessary to build a record of transparency and TIMELY release of news.
Lets hope next week we get a PR on HemaX protocol finalization for safety tests and then we can wait for early Nov news on dCellVax IND response from FDA. If things keep moving and building on this pace, 2015 will be the year we hoped 2014 would be.
